Sanofi - ADR (SNY) Company Profile & Statistics

Sanofi - ADR
SNY
(Nasdaq - US)
N/A
49.31
+2.70 (+5.79%)
in:usd•As of: Apr 25, 2024 15:59 UTC -4
Open
48.83
High
49.83
Low
48.65

About Sanofi - ADR

CEO

Paul Hudson

Headquarters

46 avenue de la grande armee

paris, i0 75017, paris

Auditor

PricewaterhouseCoopers

Employees

86,088

Share Holders

N/A

Website

www.sanofi.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Sanofi - ADR Statistics

Valuation Measures

Market Capitalization ²	124.74B
Enterprise Value	133.05B
Enterprise Value/EBITDA (ttm)	13.87
Price to Earnings Ratio (ttm)	10.86
Price to Book (mrq)	1.50
Price to Sales (ttm)	2.59
Price to Cash (ytd)	7.46

Profitability

Gross Margin (ttm)	69.41%
Operating Margin (ttm)	23.58%
Profit Margin (ttm)	11.76%
Return on Equity (ttm)	27.47%
Return on Invested Capital (ttm)	1.02%
Return on Assets (ttm)	16.07%

Income Statement

Revenue (ttm)	50.27B
Revenue Per Share (ttm)	19.87
Gross Profit (ttm)	34.86B
EBITDA (ttm)³	9.59B
Net Income Avi to Common (ttm)	5.84B
Diluted EPS (ttm)	2.36

Share Statistics

Beta (5Y Monthly)	0.61
52-Week Change	-9.00%
S&P500 52-Week Change	24.47%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	2.53B
Dividend Yield	2.88%
Float ⁴	2.50B
% Held by Insiders	1.00%
% Held by Institutions	10.04%

Balance Sheet

Total Cash (mrq)	9.43B
Total Cash Per Share (mrq)	3.73
Total Debt (mrq)	17.74B
Total Debt/Equity (mrq)	22.05%
Current Ratio (mrq)	1.27%
Quick Ratio (mrq)	0.87%
Book Value Per Share (mrq)	31.81

Cash Flow

Operating Cash Flow Per Share (ytd)	4.42
Free Cash Flow (ytd)	8.93B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Sanofi - ADR

Trade With A Regulated Broker